Treatment strategy for patients with platinum-sensitive ovarian cancer using PARP inhibitors

被引：0
|
作者：
Matsumoto, Koji [1 ]
机构：
[1] Hyogo Canc Ctr, Div Med Oncol, Akashi, Hyogo, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz336
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MS3 - 3
引用
收藏
页数：1
相关论文
共 50 条
  • [41] SEARCHING FOR THE BEST MAINTENANCE THERAPY IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: BEVACIZUMAB OR PARP-INHIBITORS? A NETWORK META-ANALYSIS
    Bartoletti, M.
    Pelizzari, G.
    Bortot, L.
    Giavarra, M.
    Vitale, M. G.
    Andreotti, V.
    Parnofiello, A.
    Scalone, S.
    Lombardi, D.
    Nicoloso, M.
    Bozza, C.
    Poletto, E.
    Sacco, C.
    Andreetta, C.
    Sorio, R.
    Puglisi, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A437 - A438
  • [42] Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
    Della Pepa, Chiara
    Banerjee, Susana
    ONCOTARGETS AND THERAPY, 2014, 7 : 1025 - 1032
  • [43] A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis
    Ji, Shiya
    Chen, Lu
    Yu, Yebo
    Chen, Xupeng
    Wei, Liwen
    Gou, Lili
    Shi, Cheng
    Zhuang, Susu
    JOURNAL OF OVARIAN RESEARCH, 2025, 18 (01)
  • [44] Effects of PARP inhibitors therapy on the PFS and OS in platinum-sensitive recurrent ovarian cancer: A meta-analysis of randomized controlled trials
    Min, B. H.
    Yoon, S. H.
    Shim, S. H.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 271 - 271
  • [45] MANAGEMENT OF FIRST RELAPSE IN PLATINUM-SENSITIVE OVARIAN CANCER
    Vieira, C.
    Teixeira, A.
    Vaz, A.
    Ferreira, A.
    Oliveira, J.
    Couto, R.
    Afonso, N.
    Sousa, S.
    Sousa, B.
    Pereira, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 215 - 215
  • [46] Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer
    Bouberhan, Sara
    Pujade-Lauraine, Eric
    Cannistra, Stephen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27) : 2424 - +
  • [47] The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer
    Gubbi, Ajit
    Kendrick, James E.
    Finkler, Neil J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (10) : 1105 - 1113
  • [48] PARP INHIBITORS AS FRONTLINE TREATMENT IN PATIENTS WITH OVARIAN CANCER
    Wright, Kevin
    ONCOLOGY-NEW YORK, 2020, 34 (03): : 86 - 86
  • [49] Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin
    Poveda, Andres
    Ray-Coquard, Isabelle
    Romero, Ignacio
    Antonio Lopez-Guerrero, Jose
    Colombo, Nicoletta
    CANCER TREATMENT REVIEWS, 2014, 40 (03) : 366 - 375
  • [50] RT in platinum-sensitive oligometastatic ovarian cancer: an alternative to delay systemic treatment
    Corrao, G.
    Lazzari, R.
    Durante, S.
    Pierini, V.
    Repetti, I.
    Lorubbio, C.
    Comi, S.
    Multinu, F.
    Cattani, F.
    Maggioni, A.
    Colombo, N.
    Jereczek-Fossa, B. A.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S681 - S682
12345